BioMrieux Company Top Insiders
| BMXMF Stock | USD 105.67 0.02 0.02% |
BioMrieux employs about 12.1 K people. The company is managed by 30 executives with a total tenure of roughly 220 years, averaging almost 7.0 years of service per executive, having 402.8 employees per reported executive. Examination of BioMrieux's management performance can provide insight into the company performance.
| Wei Ding CEO Member of the Management Committee, CEO of bioTheranostics |
| Alexandre Merieux CEO CEO, Director and Member of Strategy Committee |
BioMrieux |
BioMrieux Management Team Effectiveness
The company has return on total asset (ROA) of 0.1008 % which means that it generated a profit of $0.1008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1751 %, meaning that it generated $0.1751 on every $100 dollars invested by stockholders. BioMrieux's management efficiency ratios could be used to measure how well BioMrieux manages its routine affairs as well as how well it operates its assets and liabilities.BioMrieux Workforce Comparison
bioMrieux SA is number one stock in number of employees category among related companies. The total workforce of Diagnostics & Research industry is currently estimated at about 21,159. BioMrieux totals roughly 12,084 in number of employees claiming about 57% of equities under Diagnostics & Research industry.
The company has Profit Margin (PM) of 0.16 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.21 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.21. bioMrieux SA Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. bioMrieux SA Price Series Summation is a cross summation of BioMrieux price series and its benchmark/peer.
BioMrieux Notable Stakeholders
A BioMrieux stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioMrieux often face trade-offs trying to please all of them. BioMrieux's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioMrieux's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Wei Ding | Member of the Management Committee, CEO of bioTheranostics | Profile | |
| Alexandre Merieux | CEO, Director and Member of Strategy Committee | Profile | |
| JeanLuc Belingard | Chairman of the Board | Profile | |
| Guillaume Bouhours | Corporate Vice President CFO, Member of the Executive Board | Profile | |
| Claire Giraut | Member of the Management Committee and Corporate Vice President and CFO, Administrative Director | Profile | |
| Pierre Boulud | Corporate Vice-President Asia-Pacific Region, Industrial Unit, Investments and Strategic Planning | Profile | |
| Yasha Mitrotti | Corporate Vice President Europe, Middle East, Africa Region, Member of the Management Committee | Profile | |
| Pierre Charbonnier | Corporate Vice President Manufacturing & Supply Chain, Member of the Management Committee | Profile | |
| Randy Rasmussen | Corporate Vice President Molecular Biology, Member of the Management Committee | Profile | |
| Alain Pluquet | CTO and Corporate VP of Innovation | Profile | |
| Fanny Letier | Independent Director | Profile | |
| Philippe Archinard | Director | Profile | |
| Francois Lacoste | Member of the Management Committee, Director of Immunoassay Unit | Profile | |
| Harold Boel | Independent Director | Profile | |
| Michel Baguenault | Member of the Management Committee, Director of Human Resources and Communication | Profile | |
| Nicolas Cartier | Member of the Management Committee, Director of Industrial Microbiology Unit | Profile | |
| MariePaule Kieny | Independent Director | Profile | |
| Agnes Lemarchand | Independent Director | Profile | |
| Philippe Gillet | Independent Director | Profile | |
| Michele Palladino | Independent Director | Profile | |
| Alain Merieux | Director | Profile | |
| MarieHelene HabertDassault | Independent Director | Profile | |
| Stefan Willemsen | Group Chief Legal Officer and Corporate VP of America Region | Profile | |
| Frederic Beseme | Head CSR | Profile | |
| Kirk Ririe | Chief Innovation Officer | Profile | |
| Sylvain Morgeau | Head of Investor Relations | Profile | |
| Isabelle Tongio | Investor Relations Manager | Profile | |
| Mark Miller | Member of the Management Committee, Chief Medical Officer and Head of Regulatory Affairs | Profile | |
| Valerie Leylde | Communications HR | Profile | |
| Franois Lacoste | Ex RD | Profile |
About BioMrieux Management Performance
The success or failure of an entity such as bioMrieux SA often depends on how effective the management is. BioMrieux management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioMrieux management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioMrieux management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
bioMrieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as B-D Mrieux. bioMrieux S.A. was founded in 1963 and is headquartered in Marcy lEtoile, France. bioMrieux S.A. is a subsidiary of Institut Mrieux SA. Biomerieux operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 12084 people.
The data published in BioMrieux's official financial statements usually reflect BioMrieux's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of bioMrieux SA. For example, before you start analyzing numbers published by BioMrieux accountants, it's critical to develop an understanding of what BioMrieux's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of BioMrieux's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioMrieux's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in BioMrieux's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of bioMrieux SA. Please utilize our Beneish M Score to check the likelihood of BioMrieux's management manipulating its earnings.
BioMrieux Workforce Analysis
Traditionally, organizations such as BioMrieux use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioMrieux within its industry.BioMrieux Manpower Efficiency
Return on BioMrieux Manpower
| Revenue Per Employee | 279.4K | |
| Revenue Per Executive | 112.5M | |
| Net Income Per Employee | 49.7K | |
| Net Income Per Executive | 20M | |
| Working Capital Per Employee | 34.1K | |
| Working Capital Per Executive | 13.7M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioMrieux SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for BioMrieux Pink Sheet analysis
When running BioMrieux's price analysis, check to measure BioMrieux's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioMrieux is operating at the current time. Most of BioMrieux's value examination focuses on studying past and present price action to predict the probability of BioMrieux's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioMrieux's price. Additionally, you may evaluate how the addition of BioMrieux to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |